fortune ox feature

fortune ox feature

NEW YORK (AP) — Technology stocks pulled Wall Street to another record amid a mixed Monday of trading. The S&P 500 rose 0.2% from its all-time high set on Friday to post a record for the 54th time this year. The Dow Jones Industrial Average fell 128 points, or 0.3%, while the Nasdaq composite gained 1%. Super Micro Computer, a stock that’s been on an AI-driven roller coaster, soared 28.7% to lead the market. Following allegations of misconduct and the resignation of its public auditor , the maker of servers used in artificial-intelligence technology said an investigation found no evidence of misconduct by its management or by the company’s board. It also said that it doesn’t expect to restate its past financials and that it will find a new chief financial officer, appoint a general counsel and make other moves to strengthen its governance. Big Tech stocks also helped prop up the market. Gains of 1.8% for Microsoft and 3.2% for Meta Platforms were the two strongest forces pushing upward on the S&P 500. Intel was another propellant during the morning, but it lost an early gain to fall 0.5% after the chip company said CEO Pat Gelsinger has retired and stepped down from the board. Intel is looking for Gelsinger’s replacement, and its chair said it’s “committed to restoring investor confidence.” Intel recently lost its spot in the Dow Jones Industrial Average to Nvidia, which has skyrocketed in Wall Street’s frenzy around AI. Stellantis, meanwhile, skidded following the announcement of its CEO’s departure . Carlos Tavares steps down after nearly four years in the top spot of the automaker, which owns car brands like Jeep, Citroën and Ram, amid an ongoing struggle with slumping sales and an inventory backlog at dealerships. The world’s fourth-largest automaker’s stock fell 6.3% in Milan. The majority of stocks in the S&P 500 likewise fell, including California utility PG&E. It dropped 5% after saying it would sell $2.4 billion of stock and preferred shares to raise cash. Retailers were mixed amid what’s expected to be the best Cyber Monday on record and coming off Black Friday . Target, which recently gave a forecast for the holiday season that left investors discouraged , fell 1.2%. Walmart , which gave a more optimistic forecast, rose 0.2%. Amazon, which looks to benefit from online sales from Cyber Monday, climbed 1.4%. All told, the S&P 500 added 14.77 points to 6,047.15. The Dow fell 128.65 to 44,782.00, and the Nasdaq composite climbed 185.78 to 19,403.95. The stock market largely took Donald Trump’s latest threat on tariffs in stride. The president-elect on Saturday threatened 100% tariffs against a group of developing economies if they act to undermine the U.S. dollar. Trump said he wants the group, headlined by Brazil, Russia, India and China, to promise it won’t create a new currency or otherwise try to undercut the U.S. dollar. The dollar has long been the currency of choice for global trade. Speculation has also been around a long time that other currencies could knock it off its mantle, but no contender has come close. The U.S. dollar’s value rose Monday against several other currencies, but one of its strongest moves likely had less to do with the tariff threats. The euro fell amid a political battle in Paris over the French government’s budget . The euro sank 0.7% against the U.S. dollar and broke below $1.05. In the bond market, Treasury yields gave up early gains to hold relatively steady. The yield on the 10-year Treasury climbed above 4.23% during the morning before falling back to 4.19%. That was just above its level of 4.18% late Friday. A report in the morning showed the U.S. manufacturing sector contracted again last month, but not by as much as economists expected. This upcoming week will bring several big updates on the job market, including the October job openings report, weekly unemployment benefits data and the all-important November jobs report. They could steer the next moves for Federal Reserve, which recently began pulling interest rates lower to give support to the economy. Economists expect Friday’s headliner report to show U.S. employers accelerated their hiring in November, coming off October’s lackluster growth that was hampered by damaging hurricanes and strikes. “We now find ourselves in the middle of this Goldilocks zone, where economic health supports earnings growth while remaining weak enough to justify potential Fed rate cuts,” according to Mark Hackett, chief of investment research at Nationwide. In financial markets abroad, Chinese stocks led gains worldwide as monthly surveys showed improving conditions for manufacturing, partly driven by a surge in orders ahead of Trump’s inauguration next month. Both official and private sector surveys of factory managers showed strong new orders and export orders, possibly partly linked to efforts by importers in the U.S. to beat potential tariff hikes by Trump once he takes office. Indexes rose 0.7% in Hong Kong and 1.1% in Shanghai. AP Business Writers Matt Ott and Elaine Kurtenbach contributed.One Bio New funding goes to groundbreaking products that pour plant fibers into our favorite foods to reduce the toxic impact of sugar and lower the incidence of metabolic disorders linked to the modern processed diet SACRAMENTO, Calif. , Dec. 13, 2024 /PRNewswire/ -- One Bio , a pioneering biotechnology company committed to revolutionizing nutrition to empower people to live better, longer, has raised $27 million in Series A funding led by Alpha Edison and joined by new investors including Leaps by Bayer, Mitsui E12, Morado, ReMY, DSM-Ferminich, and Better – alongside existing investors including iSelect, Skyview Life Sciences, Collaborative and Acre. This catalytic investment round energized a unique global mix of strategic and institutional investors and is a testament to investor belief in One Bio's potential to reshape how much (and how often) the world consumes fiber, and to combat the disease epidemic linked to the modern processed diet by transforming your favorite foods into engines of good health while helping all of us reduce and eliminate the harm of sugar. One Bio has innovated a technological process that releases anti-inflammatory short chain fibers from thousands of plants, making them undetectable, more bioactive and uniquely high dose. This novel process unlocks fibers from seeds, nuts, fruits, vegetables, legumes and grains. People today consume 10X more sugar than they did 200 years ago and 90% less fiber than we evolved to. Consequently, 95% of people are running a dramatic fiber deficiency that starves the microbiome while denying our bodies of core functions for healthspan. The result is skyrocketing rates of inflammatory disease including obesity, diabetes, cardiovascular, neurodegenerative, cancer and autoimmunity. One Bio promises a meaningfully positive shift in these alarming public health outcomes by not only eliminating traditional barriers to fiber consumption - like taste, texture, and appearance - but also reframing naturally-derived fiber as an essential but *undetectable* ingredient in our favorite foods and beverages. As humans evolved, our beneficial gut microbes co-evolved to unlock and consume the sugars bound in the rich diversity of fibers present in plant foods to produce molecules we need to provide core functions including balancing our blood glucose, regulating mood & energy, and making us feel satiated. But modern diets composed of processed foods have isolated the sugars and discarded the fibers. One Bio short chain fibers can even provide an offramp to reduce the population's reliance on GLP-1s to treat chronic metabolic diseases: increasing consumption of high-fiber foods can prevent such diseases in the first place. "Modern food processing techniques strip plant fibers from our foods and starve the microbiome of the nutrients it needs to make us healthy. One Bio works to help us restore core functionality to our diet like blood glucose regulation and mood & energy balance. We aim to avoid and reverse the negative impact of today's processed food diet which accounts for 70% of calories consumed. We have the opportunity to offer industry and people an exponentially better set of choices than those on shelves today," said Matt Barnard , Co-founder and CEO of One Bio . " One Bio puts thriving microbiomes to work delivering longevity, aiding digestion and providing the fuel we need to maximize health," he added. "Faced with endless shelves of processed and packaged foods, and surrounded by chronic diseases, consumers are rapidly awakening to the power of the gut microbiome. An avalanche of signals points to a large pool of latent demand. This is One Bio's market," added Nate Redmond of Alpha Edison . " One Bio enables their partners to deliver functional products that reshape global health and unlock growth. We are thrilled to be working with Matt and the talented, passionate leaders who are building a category leading platform company. For more information about One Bio , please visit one.bio . About One Bio : One Bio is a biotechnology company returning healthspan to our diet by reintroducing active plant fibers to our food and reshaping how we approach health and nutrition in everyday products. Using their cutting-edge technology, One Bio has demonstrated its ability to solve malnutrition in the modern diet. The company specializes in releasing short chain fibers from plants, while making them easily consumable and highly effective to invigorate our microbiome and immune system. Through its innovative solutions and strategic partnerships, One Bio aims to eradicate inflammatory disease and help people thrive. Press contact: Original Strategies Simone Hassan-Bey simone@originalstrategies.com View original content to download multimedia: https://www.prnewswire.com/news-releases/one-bio-secures-27-million-in-series-a-funding-to-revolutionize-nutrition-with-launch-of-breakthrough-technology-making-high-dose-anti-inflammatory-plant-fiber-imperceptible-in-food-and-beverage-for-the-first-time-302331656.html SOURCE One Bio

Today's fortune: Dec. 3, 2024NEW YORK (AP) — Top-ranked chess player Magnus Carlsen is headed back to the World Blitz Championship on Monday after its governing body agreed to loosen a dress code that got him fined and denied a late-round game in another tournament for refusing to change out of jeans . Lamenting the contretemps, International Chess Federation President Arkady Dvorkovich said in a statement Sunday that he'd let World Blitz Championship tournament officials consider allowing “appropriate jeans” with a jacket, and other “elegant minor deviations” from the dress code. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get any of our free email newsletters — news headlines, obituaries, sports, and more.

TORONTO (AP) — Prime Minister Justin Trudeau told Donald Trump that Americans would also suffer if the president-elect follows through on a plan to impose sweeping tariffs on Canadian products , a Canadian minister who attended their recent dinner said Monday. Trump threatened to impose tariffs on products from Canada and Mexico if they don’t stop what he called the flow of drugs and migrants across their borders with the United States. He said on social media last week that he would impose a 25% tax on all products entering the U.S. from Canada and Mexico as one of his first executive orders. Canadian Public Safety Minister Dominic LeBlanc, whose responsibilities include border security, attended a dinner with Trump and Trudeau at Trump’s Mar-a-Lago club on Friday. Trudeau requested the meeting in a bid to avoid the tariffs by convincing Trump that the northern border is nothing like the U.S. southern border with Mexico . "The prime minister of course spoke about the importance of protecting the Canadian economy and Canadian workers from tariffs, but we also discussed with our American friends the negative impact that those tariffs could have on their economy, on affordability in the United States as well," LeBlanc said in Parliament. If Trump makes good on his threat to slap 25% tariffs on everything imported from Mexico and Canada, the price increases that could follow will collide with his campaign promise to give American families a break from inflation. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

MagicRoll: AI-powered video editing tool

TORONTO (AP) — Prime Minister Justin Trudeau told Donald Trump that Americans would also suffer if the president-elect follows through on a plan to impose sweeping tariffs on Canadian products , a Canadian minister who attended their recent dinner said Monday. Trump threatened to impose tariffs on products from Canada and Mexico if they don’t stop what he called the flow of drugs and migrants across their borders with the United States. He said on social media last week that he would impose a 25% tax on all products entering the U.S. from Canada and Mexico as one of his first executive orders. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.None

Key Leadership Appointments Bring New Skills and Capabilities to Organization EMERYVILLE, Calif. , Dec. 13, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the recent appointments of Dan Maziasz as Chief Business Officer, Cara Bauer as Chief Human Resources Officer, and Tracy Rossin as Senior Vice President of Corporate Affairs, Communications and Investor Relations. "I'm pleased to welcome three industry leaders to our Kyverna team," said Warner Biddle , Chief Executive Officer of Kyverna. "Dan, Cara and Tracy bring important new skills and capabilities to Kyverna as we continue to support the company's next phase of growth and work to bring a transformative change to patients living with severe autoimmune diseases." Mr. Maziasz brings over 25 years of leadership and business experience across several leading biotechnology and large pharmaceutical companies. Mr. Maziasz most recently served as Chief Business Officer at Atara Biotherapeutics, the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. At Atara, Mr. Maziasz led various corporate initiatives including strategic planning, licensing transactions with industry partners, and research collaborations with academic groups. Before his time at Atara, Mr. Maziasz was Vice President, Corporate Strategy and Business Development at Kite Pharma, a global cell therapy leader, prior to its acquisition by Gilead Sciences. Mr. Maziasz also spent more than a decade at Amgen, where he held roles of increasing responsibility in the US, Europe , and Asia across business development, corporate strategy, finance, and commercial functions. Ms. Bauer brings more than 25 years of experience in global human resources leadership to Kyverna, having served most recently as Global Head of Human Resources at Kite, a Gilead Company, where she oversaw all HR strategy and operations during a period of hypergrowth and global expansion which strengthened the company's leadership position in cell therapy. Prior to this role, she served as the Global Head of HR for the Entertainment Division at Riot Games where she worked directly with the founders to build an Entertainment Studio separate from the core gaming business. Ms. Bauer has also held various HR leadership roles at companies such as Netflix, Amgen, Gartner and Novo Nordisk. Ms. Rossin brings more than 20 years of strategic communications experience to Kyverna, having most recently served as the Head of Public Affairs at Kite, where she was responsible for leading corporate, product and employee communications in addition to patient advocacy. Prior to this role, she served as Vice President, Global Head of Communications at Innate Pharma, an oncology-focused biotech company, where she led both corporate and financial communications. Ms. Rossin also spent more than 12 years at AstraZeneca/MedImmune, where she held multiple U.S. and global communications roles for key therapeutic areas across AstraZeneca's portfolio before serving as the Head of Corporate Affairs at MedImmune, the global biologics research and development arm of AstraZeneca. Before joining AstraZeneca, she held various positions at global public relations agencies working with corporate and healthcare related clients. Inducement Grant In connection with the appointment of Mr. Maziasz as Kyverna's Chief Business Officer, on December 9, 2024 , Kyverna granted Mr. Maziasz an option to purchase 350,000 shares of its common stock (Option). The Option was granted pursuant to the Kyverna Therapeutics, Inc. 2024 Inducement Equity Incentive Plan, as approved by the Compensation Committee of Kyverna's Board of Directors on September 14, 2024 , and was granted as an inducement material to Mr. Maziasz's employment with Kyverna in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price of the Option was $4.86 , the closing price of Kyverna's common stock on December 9, 2024 , the date of grant. The Option will vest over four years, with 25% of the total number of shares subject to the Option vesting on the one-year anniversary of Mr. Maziasz's appointment and 1/48th of the total number of shares subject to the Option vesting monthly thereafter, subject in each case to Mr. Maziasz's continued service to Kyverna on each vesting date. Kyverna is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). About Kyverna Therapeutics Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead CAR T-cell therapy candidate, KYV-101 is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. Kyverna's pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. For more information, please visit https://kyvernatx.com . Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: the potential impact of the clinical outcomes from the ongoing clinical programs; the potential impact of the new data on the treatment efficacy and safety profile of KYV-101; the potential that the results of the ongoing trials could drastically change the treatment landscape for the targeted autoimmune diseases; Kyverna's goals to develop certain paradigm-shifting treatment options; the potential for KYV-101 to provide durable, immunosuppressant-free remission for autoimmune disease patients; Kyverna's beliefs about the differentiated properties of KYV-101; and Kyverna's clinical trials, investigator-initiated trials and named-patient activities. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of Kyverna's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna's management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Contact: Investors: InvestorRelations@kyvernatx.com Media: media@kyvernatx.com View original content to download multimedia: https://www.prnewswire.com/news-releases/kyverna-therapeutics-strengthens-leadership-team-to-accelerate-next-phase-of-growth-302331659.html SOURCE Kyverna Therapeutics